Latest News and Press Releases

MONTRÉAL, 04 juin 2019 (GLOBE NEWSWIRE) -- Angiochem Inc. (“Angiochem”) a annoncé aujourd’hui que le Gouvernement du Québec, par l’entremise du programme BioMed Propulsion, lui a accordé un...

MONTREAL, June 04, 2019 (GLOBE NEWSWIRE) -- Angiochem Inc. (“Angiochem”) announced today that it has been granted a $4 million loan from the Quebec Government through its BioMed Propulsion program....

MONTREAL, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Angiochem Inc. (“Angiochem”) announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special...

MONTREAL, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Angiochem Inc. (“Angiochem”) announced today that it has secured a $7.5 million Series C financing to pursue its development plan. Angiochem is currently...

HONG KONG, CHINA and MONTREAL, QC--(Marketwired - January 03, 2018) - Angiochem Inc. and Xinogen (Hong Kong) Pharma Co. Ltd. ("Xinogen"), a wholly-owned subsidiary of Beijing Shenogen Pharma Group...

MONTREAL, QC--(Marketwired - November 14, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make an...

MONTREAL, QC--(Marketwired - October 17, 2016) - Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, recently presented data...

MONTREAL, QC--(Marketwired - October 11, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make an...

MONTREAL, QC--(Marketwired - October 03, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make a...

MONTREAL, QC--(Marketwired - June 23, 2016) - Angiochem, a biotechnology company developing proprietary peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, today announced...